Immunovaccine Inc (IMV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Immunovaccine Inc (IMV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH139059D
  • |
  • Pages: 67
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Immunovaccine Inc (IMV), formerly Rhino Resources Inc. is a clinical-stage biopharmaceutical company that focuses on the development of cancer immunotherapies and infectious disease vaccines. The company develops its products based on DepoVax platform, a vaccine adjuvant and delivery platform technology. Its immuno oncology pipeline products are intended for the treatment of ovarian, diffuse large B cell lymphoma (DLBCL) tumors and human papillomavirus (HPV) cervical cancer. Its infectious disease product candidates are intended for the treatment of respiratory syncytial virus, malaria and others. The company has collaboration with various universities, research institutes and other vaccine development companies to enhance its product candidates for applications in cancer and infectious diseases. IMV is headquartered in Halifax, Nova Scotia, Canada.

Immunovaccine Inc (IMV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immunovaccine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Immunovaccine Enters into Agreement with University of Edinburgh 11

Immunovaccine Forms Partnership with UConn Health 11

Immunovaccine Enters into Agreement with Leidos 12

Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 13

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 14

ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 15

Licensing Agreements 16

Immunovaccine Enters into Licensing Agreement with PharmAthene 16

Equity Offering 17

Immunovaccine Raises USD6 Million in Private Placement of Shares 17

Immunovaccine Raises USD6.2 Million in Private placement of Units 18

Immunovaccine Raises USD8.7 Million in Public Offering of Units 19

Immunovaccine to Raise USD1.6 Million in Private Placement of Shares 20

Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 21

Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 22

Immunovaccine Completes Private Placement Of Shares For US$4 Million 23

Immunovaccine Completes Private Placement Of Units For US$1.6 Million 24

Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 26

Immunovaccine Inc-Key Competitors 28

Key Employees 29

Locations And Subsidiaries 30

Head Office 30

Recent Developments 31

Financial Announcements 31

Mar 30, 2017: Immunovaccine Announces 2016 Year-End Results 31

Nov 08, 2016: Immunovaccine Announces Third Quarter 2016 Financial Results and Provides Corporate Update 35

Aug 09, 2016: Immunovaccine Provides Corporate Update and Announces Second Quarter 2016 Financial Results 37

May 10, 2016: Immunovaccine Announces Financial Results for Quarter Ended March 31, 2016 43

Mar 29, 2016: Immunovaccine Announces 2015 Year-End Results 45

Corporate Communications 47

Feb 03, 2017: Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe as CFO 47

Nov 01, 2016: Immunovaccine Appoints Gabriela Rosu, M.D., as Company's First Chief Medical Officer 48

Oct 03, 2016: Immunovaccine Announces Transition of Chief Financial Officer Role 49

Apr 15, 2016: Immunovaccine Elects Medicago CEO Andy Sheldon as Board Chairman; Reports Results of the Annual General Meeting (AGM) 50

Apr 13, 2016: Immunovaccine Names Frederic Ors Chief Executive Officer; Andy Sheldon, Medicago CEO, to Join Board of Directors 51

Mar 15, 2016: Immunovaccine Announces Management Team Changes 52

Product News 53

09/23/2016: Researchers to Present Data on Immunovaccine Infectious Disease Pipeline at Three International Conferences 53

Product Approvals 54

Nov 22, 2016: The European Medicines Agency Grants Orphan Drug Designation Status to Immunovaccine's DPX-Survivac in Ovarian Cancer 54

Clinical Trials 55

Nov 03, 2016: Neoepitope Peptides Formulated in Immunovaccine's DepoVax Vaccine Platform Show Significant Positive Results in Preclinical Studies 55

Oct 13, 2016: Immunovaccine Announces Positive Phase 1 Topline Data for DepoVax based Respiratory Syncytial Virus Vaccine Candidate 56

Sep 08, 2016: Immunovaccine Announces Dosing of First Patient in Phase 1b Clinical Trial for DPX-Survivac in Combination with Incyte's IDO1 Enzyme Inhibitor Epacadostat 58

Aug 25, 2016: Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program with DPX-Survivac in Ovarian Cancer 60

Aug 08, 2016: Anti-Cocaine Vaccine Approved for Clinical Study in Humans 62

Jul 06, 2016: Immunovaccine Announces Positive Interim Phase 1 Data for DepoVax-Based Respiratory Syncytial Virus Vaccine Candidate 63

Jan 11, 2016: Immunovaccine Announces U.S. FDA and Health Canada Clearance to Initiate Phase 1b Clinical Trial for DPX-Survivac in Combination with Incyte's IDO1 Inhibitor Epacadostat in Recurrent Ovarian Cancer 65

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67

List of Figures

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Immunovaccine Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immunovaccine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immunovaccine Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Immunovaccine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Immunovaccine Enters into Agreement with University of Edinburgh 11

Immunovaccine Forms Partnership with UConn Health 11

Immunovaccine Enters into Agreement with Leidos 12

Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 13

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 14

ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 15

Immunovaccine Enters into Licensing Agreement with PharmAthene 16

Immunovaccine Raises USD6 Million in Private Placement of Shares 17

Immunovaccine Raises USD6.2 Million in Private placement of Units 18

Immunovaccine Raises USD8.7 Million in Public Offering of Units 19

Immunovaccine to Raise USD1.6 Million in Private Placement of Shares 20

Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 21

Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 22

Immunovaccine Completes Private Placement Of Shares For US$4 Million 23

Immunovaccine Completes Private Placement Of Units For US$1.6 Million 24

Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 26

Immunovaccine Inc, Key Competitors 28

Immunovaccine Inc, Key Employees 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Immunovaccine Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16235
Site License
USD 500 INR 32470
Corporate User License
USD 750 INR 48705

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com